These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

650 related articles for article (PubMed ID: 11592341)

  • 1. Plasma pharmacokinetics and bioavailability of 1-(2-chloroethyl)-3-sarcosinamide-1-nitrosourea after intravenous and oral administration to mice and dogs.
    Supko JG; Garcia-Carbonero R; Puchalski TA; Malspeis L
    Cancer Chemother Pharmacol; 2001 Sep; 48(3):202-8. PubMed ID: 11592341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SarCNU, a nitrosourea analog on a day 1, 5, and 9 oral schedule: a phase I and pharmacokinetic study in patients with advanced solid tumors.
    Panasci L; Stinson SF; Melnychuk D; Sandor V; Miller WH; Batist G; Patenaude F; Bangash N; Panarello L; Alaoui-Jamali M; Sausville E
    J Clin Oncol; 2003 Jan; 21(2):232-40. PubMed ID: 12525514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2-Chloroethyl-3-sarcosinamide-1-nitrosourea, a novel chloroethylnitrosourea analogue with enhanced antitumor activity against human glioma xenografts.
    Marcantonio D; Panasci LC; Hollingshead MG; Alley MC; Camalier RF; Sausville EA; Dykes DJ; Carter CA; Malspeis L
    Cancer Res; 1997 Sep; 57(18):3895-8. PubMed ID: 9307267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specific high-performance liquid chromatographic assay with ultraviolet detection for the determination of 1-(2-chloroethyl)-3-sarcosinamide-1-nitrosourea in plasma.
    Supko JG; Phillips LR; Malspeis L
    J Chromatogr B Biomed Appl; 1996 Mar; 677(2):351-62. PubMed ID: 8704941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between drug delivery and the intra-arterial infusion rate of SarCNU in C6 rat brain tumor model.
    Takeda N; Diksic M
    J Neurooncol; 1999 Feb; 41(3):235-46. PubMed ID: 10359143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of resistance to (2-chloroethyl)-3-sarcosinamide-1-nitrosourea (SarCNU) in sensitive and resistant human glioma cells.
    Skalski V; Yarosh DB; Batist G; Gros P; Feindel W; Kopriva D; Panasci LC
    Mol Pharmacol; 1990 Sep; 38(3):299-305. PubMed ID: 2402223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transport of (2-chloroethyl)-3-sarcosinamide-1-nitrosourea in the human glioma cell line SK-MG-1 is mediated by an epinephrine-sensitive carrier system.
    Noë AJ; Malapetsa A; Panasci LC
    Mol Pharmacol; 1993 Jul; 44(1):204-9. PubMed ID: 8341272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altered cytotoxicity of (2-chloroethyl)-3-sarcosinamide-1-nitrosourea in human glioma cell lines SK-MG-1 and SKI-1 correlates with differential transport kinetics.
    Noë AJ; Malapetsa A; Panasci LC
    Cancer Res; 1994 Mar; 54(6):1491-6. PubMed ID: 8137253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats.
    Egorin MJ; Lagattuta TF; Hamburger DR; Covey JM; White KD; Musser SM; Eiseman JL
    Cancer Chemother Pharmacol; 2002 Jan; 49(1):7-19. PubMed ID: 11855755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2-Chloroethyl-3-sarcosinamide-1-nitrosourea (SarCNU) inhibits prostate carcinoma cell growth via p53-dependent and p53-independent pathways.
    Huynh H; Nguyen TH; Panasci L; Do P
    Cancer; 2004 Dec; 101(12):2881-91. PubMed ID: 15529313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
    Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
    Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
    J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of 11C-labelled BCNU and SarCNU in gliomas studied by PET.
    Mitsuki S; Diksic M; Conway T; Yamamoto YL; Villemure JG; Feindel W
    J Neurooncol; 1991 Feb; 10(1):47-55. PubMed ID: 1902507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Both extraneuronal monoamine transporter and O(6)-methylguanine-DNA methyltransferase expression influence the antitumor efficacy of 2-chloroethyl-3-sarcosinamide- 1-nitrosourea in human tumor xenografts.
    Chen ZP; Wang ZM; Carter CA; Alley MC; Mohr G; Panasci LC
    J Pharmacol Exp Ther; 2001 Mar; 296(3):712-5. PubMed ID: 11181897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the safety and pharmacokinetics of ST-246® after i.v. infusion or oral administration in mice, rabbits and monkeys.
    Chen Y; Amantana A; Tyavanagimatt SR; Zima D; Yan XS; Kasi G; Weeks M; Stone MA; Weimers WC; Samuel P; Tan Y; Jones KF; Lee DR; Kickner SS; Saville BM; Lauzon M; McIntyre A; Honeychurch KM; Jordan R; Hruby DE; Leeds JM
    PLoS One; 2011; 6(8):e23237. PubMed ID: 21858040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique.
    Heikkinen H; Saraheimo M; Antila S; Ottoila P; Pentikäinen PJ
    Eur J Clin Pharmacol; 2001; 56(11):821-6. PubMed ID: 11294372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration.
    Marzolini C; Decosterd LA; Shen F; Gander M; Leyvraz S; Bauer J; Buclin T; Biollaz J; Lejeune F
    Cancer Chemother Pharmacol; 1998; 42(6):433-40. PubMed ID: 9788568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and tissue distribution of halofuginone (NSC 713205) in CD2F1 mice and Fischer 344 rats.
    Stecklair KP; Hamburger DR; Egorin MJ; Parise RA; Covey JM; Eiseman JL
    Cancer Chemother Pharmacol; 2001 Nov; 48(5):375-82. PubMed ID: 11761455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extraneuronal monoamine transporter expression and DNA repair vis-à-vis 2-chloroethyl-3-sarcosinamide-1-nitrosourea cytotoxicity in human tumor cell lines.
    Chen ZP; Remack J; Brent TP; Mohr G; Panasci LC
    Clin Cancer Res; 1999 Dec; 5(12):4186-90. PubMed ID: 10632359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1.
    Egorin MJ; Zuhowski EG; Rosen DM; Sentz DL; Covey JM; Eiseman JL
    Cancer Chemother Pharmacol; 2001 Apr; 47(4):291-302. PubMed ID: 11345645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.